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Abstract 
BACKGROUND: Prevalence of obesity increased sharply recently; it was associated with an increased 
prevalence of several cardiometabolic diseases. Reduced glucagon-like peptide 1 (GLP-1) secretion is observed 
among obese subjects in many studies, and it may mediate the failure of insulin secretion response to food intake.  
AIM: To evaluate the pattern of fasting and post 75 g glucose loading of GLP-1 levels in obese and non-obese 
subjects.  
METHODS: An experimental study on the pattern of GLP-1 levels in fasting state and response in post 75 g 
glucose loading in obese and non-obese subjects, was conducted. Sixteen obese and 16 non-obese subjects 
were enrolled in the study, with age- and sex-matching in both groups. GLP-1 levels were measured at fasting 
state (0), 15, 30, 60, and 120 minutes post-glucose loading. 
RESULTS: The GLP-1 response to glucose loading were similar in obese and non-obese subjects, which 
increased from fasting state to post glucose loading and reaching the peak levels in 15 minutes, then declined 
until the end of observation. There was tendency that GLP-1 levels in fasting state and post glucose loading were 
lower in obese subjects compared to in non-obese subjects (in fasting state, 5.67 vs. 6.16 ng/mL, P = 0.338; in 15 
minutes, 6.20 vs. 6.94 ng/mL, P = 0.239; in 30 minutes 6.20 vs. 6.90 ng/mL, P = 0.264; in 60 minutes, 5.77 vs. 
6.12 ng/mL, P = 0.242), but the difference were not statistically significant, except in 120 minutes (5.24 vs. 6.67 
ng/mL, P = 0.049; in obese and non-obese subjects, respectively). Similar finding was also seen in the pattern of 
response (delta) of GLP-1 from time-to-time observation among obese and non-obese subjects (0-15 minutes 
[0.52 vs. 0.8 ng/mL, P = 0.350], 0-30 minutes [0.53 vs. 0.74, P = 0.550], 0-60 minutes [0.11 vs. 0.31 ng/mL, P = 
0.546], in 0-120 minute [-0.42 vs. 0.31, P = 0.006]). 
CONCLUSIONS: The patterns of GLP-1 levels post glucose loading were similar in obese and non-obese 
subjects which increased from fasting state to post glucose loading, reaching the peak levels in 15 minutes and 
then declined until the end of observation, except in non-obese subjects where the GLP-1 levels were increased 
at 120 minutes. There was a tendency of GLP-1 levels in fasting state and post-glucose loading to be lower in 
obese subjects compared within non-obese subjects. 
 
 
 
 
Introduction 
 
Based on the World Health Organization 
report, the prevalence of obesity has doubled between 
1980 and 2008. The highest prevalence of obesity is 
presented in the American region (62% have 
overweight, and 26% are obese), and the lowest 
prevalence is shown in Southeast Asia (14% are 
overweight, and 3% experience obesity). As many as 
2.8 million people die each year from being 
overweight or obese [1]. Overweight and obesity 
trigger 44% of the incidence of diabetes, 23% of the 
incidence of ischemic heart disease and around 7-
41% of cancer incidence [2]. The prevalence of 
obesity in many countries tends to be increased, 
including in Indonesia. Data from Basic Health 
Research in 2007 and 2013 reported by Ministry of 
Health Republic of Indonesia revealed that the 
prevalence of obesity in adults was increased from 
13.9% to 19.7% in men and from 14.8% to 32.9% in 
women, and followed by increasing the prevalence of 
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diabetes from 5.7% to 6.9% [3], [4]. A survey on 
obesity and diabetes in Bali by Suastika et al., in 2011 
showed that the prevalence of central obesity, 
impaired fasting glycemia and diabetes in adults were 
35%, 13.1% and 5.9%, respectively [5]. 
 
Glucagon-like peptide-1 (GLP-1) is an incretin 
hormone produced by L cells in the small intestine 
and released in response to meal intake.
 
Postprandial 
GLP-1 secretion in response to oral carbohydrate 
meal was reduced in obese subjects [6]. The 
ADDITION-PRO Study published by Faerch et al., in 
2015 revealed that subjects with overweight and 
obesity had up to 20% reduced GLP-1 response 
compared with normal weight subjects. And, 
compared to individuals with normal glucose tolerance 
(NGT), women with prediabetes or type 2 diabetes 
mellitus (T2DM) had 25% lower GLP-1 response to an 
OGTT, and both in women and men with prediabetes 
or T2DM had 16-21% lower 120-minutes GLP-1 
concentration [7]. A similar finding was seen in a study 
by Munoz et al., that subjects with normal weight had 
lower fasting GLP-1 levels significantly compared to 
subjects with overweight and obesity (8.27 vs 9.02 vs 
8.86 pM, respectively) [8]. 
Impaired function of GLP-1 contributes to the 
impairment of insulin secretion in patients with type 2 
diabetes mellitus (T2DM) [9]. A study on GLP-1 levels 
among normoglycemia and type 2 diabetes in 
Sanglah Hospital showed that fasting and 1-hour post 
75 g glucose loading GLP-1 levels was lower in type 2 
diabetes than in normoglycemic subjects [10]. 
Since there were in the variations data from 
several studies and there was no detailed data on the 
patterns of GLP-1 levels post glucose loading in 
obese and non-obese subjects in Indonesia, the study 
was conducted to evaluate the pattern of fasting and 
post 75 g glucose loading of GLP-1 levels in obese 
compared with non-obese subjects. Hopefully, the 
result of the study can be used to determine the peak 
response of GLP-1 levels post loading in the term for 
further study. 
 
 
Methods 
 
An experimental study on fasting and post 75 
g glucose loading of GLP-1 levels among obese and 
non-obese subjects at Sanglah Hospital during April-
June 2018 was carried out. Total of 32 subjects, 16 
obese and 16 non-obese subjects was enrolled in the 
study and was matched for age and sex in both 
groups. Age of subjects was between 20-50 years 
(31.46 ± 4.81 years), and they had no diabetes. 
Subjects with obesity were confirmed if body mass 
index (BMI) ≥ 25 kg/m
2
 and waist circumference (WC) 
≥ 90 cm for men and ≥ 80 cm for women; and non-
obese subjects were determined if BMI < 25 kg/m
2
 
and WC < 90 for men and < 80 for women.  
Blood samples for determination of plasma 
GLP-1 levels were drawn in fasting state (0
 
minutes), 
15, 30, 60, and 120
 
minutes post 75 g glucose 
loading. Subjects were fasting for at least 8-12 hours 
before performing the procedure; after drawing blood 
samples in fasting state, subjects drank 75 g 
anhydrous glucose dissolved in 250 ml water. The 
plasma human GLP-1 was measured by Elisa kit with 
a double antibody sandwich method produced by 
Yanaihara Institute Inc. (multispecies specificity), Cat. 
No. RSCYK160R.  
The study was approved by the Ethical 
Committee of the Faculty of Medicine, Udayana 
University and Sanglah Hospital (No. 
2145/UN.14.2/KEP/2017), and it was authorised by 
the Director of Sanglah Hospital (No. 
LB.02.01/IXIV.2.2.1/34463/2017). All subjects were 
given information regarding this study and signed the 
informed consent. This study was conducted by the 
Declaration of Helsinki. 
Data were expressed descriptively in mean ± 
SD and analysed for normality by Shapiro-Wilk test. 
The difference of plasma GLP-1 levels pattern among 
obese and non-obese subjects was analyzed by 
multivariate analysis with the general linear model 
repeated measurement. In all statistical analyses, 
values of P < 0.05 were considered to indicate a 
significant difference between means.  
 
 
Results 
 
The experimental study enrolled 32 subjects 
consist of each 16 subjects with obesity and 16 
subjects without obesity was conducted. The mean 
age was 31.56 years in obese subjects, and 31.37 
years in non-obese subjects (P = 0.914), BMI was 
31.10 kg/m2 in obese subjects and 21.71 kg/m2 in 
non-obese, and WC was 97.31 cm in obese subjects 
and 77.62 cm in non-obese subjects. Male to female 
ratios in obese was 8/8 and in non-obese subjects 
was 9/7 (P = 0.723) (Table 1).  
Table 1: Characteristic of subjects 
Variables Obese subjects Non-obese subjects P 
Sex (male/female ratio) 8/8 9/7 0.723 
Age (years) 31.56 ± 4l.76 31.37 ± 5.03 0.914 
Height (cm) 164.40 ± 9.89 163.25 ± 10.16 0.747 
Weight (kg) 84.74 ± 15,94 58.08 ± 9.10 < 0.001 
Body mass index (kg/m
2
) 31.10 ± 2,91 21.71 ± 1.69 < 0.001 
Waist circumference (cm) 97.31 ± 10.38 77.62 ± 6.92 < 0.001 
 
The general patterns of GLP-1 levels post 
glucose loading were similar in obese and non-obese 
subjects, who increased from fasting state to post 
glucose loading and reaching the peak levels in 15 
minutes then declined until the end of observation, 
except in non-obese subjects where the GLP-1 levels 
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were increased at 120 minutes although it never 
reached the peak levels.  
Table 2: GLP-1 levels in fasting state and after 75 g glucose 
loading in obese and non-obese subjects 
GLP-1 levels (ng/mL) Obese subjects Non-obese subjects P 
Fasting state (0
 
minutes) 5.67 ± 2.14 6.16 ± 2.85 0.338 
15
 
minutes 6.20 ± 2.21 6.94 ± 3.21 0.239 
30
 
minutes 6.20 ± 2.19 6.90 ± 2.90 0.264 
60
 
minutes 5.77 ± 2.29 6.12 ± 2.47 0.242 
120
 
minutes 5.24 ± 2.04 6.67 ± 2.87 0.049 
 
There was tendency (indicated by absolute 
levels) that GLP-1 levels in fasting state and post 
glucose loading were lower in obese subjects 
compared to in non-obese subjects (in fasting state, 
5.67 vs. 6.16 ng/mL, P=0.338; in 15 minutes, 6.20 vs. 
6.94 ng/mL, P = 0.239; in 30 minutes 6.20 vs. 6.90 
ng/mL, P = 0.264; in 60 minutes, 5.77 vs. 6.12 ng/mL, 
P = 0.242), but the difference were not statistically 
significant, except in 120 minutes (5.24 vs. 6.67 
ng/mL, P = 0.049; in obese and non-obese subjects, 
respectively) (Table 2 and Figure 1). 
 
Figure 1: GLP-1 levels in fasting state and after 75 g glucose 
loading in obese and non-obese subjects 
 
In this study we also compared the difference 
or delta (∆) of GLP-1 levels between fasting state (0 
minutes) and 15 minutes, 0
 
and 30
 
minutes, 0
 
and 60
 
minutes, and 0
 
and 120 minutes among obese and 
non-obese subjects. Similar like above finding, 
although obese subjects showed lower response of 
GLP-1 post glucose loading compared to non-obese 
subjects, actually there were no significant difference 
of ∆GLP-1 levels in 0-15
 
minutes (0.52 vs. 0.8 ng/mL, 
P=0.350), in 0-30
 
minutes (0.53 vs. 0.74, P = 0.550), 
and 0-60 minutes (0.11 vs. 0.31 ng/mL, P = 0.546), 
except in 0-120
 
minute (-0.42 vs. 0.31, P = 0.006) 
between obese and non-obese subjects (Table 3). 
Table 3: Delta () GLP-1 levels after 75 g glucose loading in 
obese and non-obese subjects  
Delta (Δ)GLP-1 (ng/mL) Obese subjects Non-obese subjects P 
ΔGLP-1 (0 – 15) 0.52 ± 0.84 0.80 ± 0.70 0.350 
ΔGLP-1 (0 – 30) 0.53 ± 0.86 0.74 ± 1.12 0.550 
ΔGLP-1 (0 – 60) 0.11 ± 0.97 0.31 ± 0.92 0.546 
ΔGLP-1 (0 – 120) -0.42 ± 0.56 0.31 ± 0.92 0.006 
 
 
Discussion 
 
The main objective of this study was to know 
the pattern of GLP-1 levels in fasting state and post-
glucose loading. Our findings showed that the GLP-1 
levels in fasting state and post-glucose loading were 
lower, but there was no significant difference, in obese 
compared to non-obese subjects, except at 120 
minutes; and the pattern of GLP-1 levels in obese and 
non-obese subjects was very similar, except at 120 
minutes. Peak GLP-1 levels in this study was noted in 
15 minutes post-glucose loading both in obese and 
non-obese subjects. The response of GLP-1 
measured by the delta of GLP-1 (0-15, 15-30, 30-60, 
60-120 minutes) showed a similar figure with the 
absolute GLP-1 levels (above). In non-obese subjects, 
although there was increased of GLP-1 levels at 120 
minutes, statistically was not different from the GLP-1 
levels at 60 minutes. 
The pattern is almost similar to other studies 
already conducted. Adam et al., in their study reported 
that peak levels of GLP-1 after ingestion of 
galactose/guar gam and standard breakfast was 
observed at 30 minutes and declined during 
observation at 60, 90, and 120 minutes. In their study 
there was no difference in GLP-1 levels at 0, 30, 60, 
90, and 120 minutes in normal weight and obese 
subjects after ingestion galactose/guar gam and 
standard breakfast, except in 30 minutes after 
ingestion standard breakfast that GLP-1 levels at 30 
minutes found higher in normal weight than those in 
obese subjects [11]. Report from Danish ADDITION-
PRO study population on GLP-1 levels at 0 minutes, 
30 minutes, and 120 minutes after glucose loading 
showed similar patterns of GLP-1 levels which 
increased sharply at 30 minutes from fasting state and 
declined at 120 minutes among 5 groups of subjects. 
Levels of GLP-1 at fasting state, 30 and 120 minutes 
were not different significantly among subjects with 
normal glycemic tolerance, impaired fasting glycemia 
(IFG), impaired glucose tolerance (IGT), IFG+IGT, 
and T2DM; except women with IFG+IGT and T2DM 
had lower GLP-1 levels at 120 minutes [7]. A study by 
Munoz et al. found that fasting GLP-1 in normal 
weight was lower than in overweight and in obese 
subjects, and higher fasting GLP-1 in overweight than 
obesity [8]. GLP-1 levels profile during OGTT in this 
study was similar to the observation by Manell et al., 
which the peak GLP-1 levels was noted at 15 minutes 
and declined until 120 minutes observation. 
Postprandial GLP-1 levels tended to be lower in 
adolescents with obesity, impaired glucose tolerance 
and T2DM compared to lean adolescents. In fasting 
state, GLP-1 levels in obese adolescents with normal 
glucose tolerance was higher compared with lean 
adolescents with normal glucose tolerance, 
adolescents with obesity and IGT and with obesity 
and T2DM. The finding was different in our study, and 
there are several studies where GLP-1 levels in 
fasting state among non-obese were higher than 
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those in obese subjects [12].  
In this study, although fasting GLP-1 levels 
tend to be lower in obese compared to non-obese 
subjects, we observed no statistically significant 
difference. This result might be caused by the 
inclusion of subjects that were overweight (BMI 
between 23 to < 25 kg/m
2
) in the non-obese group; 
which might influence the result. 
There were several studies on GLP-1 
response to glucose loading among the Asian 
population reported. A study from Malaysia in subjects 
with young-onset T2DM and healthy control showed 
that Asian young-onset T2DM showed similar GLP-1 
response to oral glucose as a control but reduced 
incretin effects, beta cell functions, and insulin 
sensitivity. The peak GLP-1 levels were observed at 
15 minutes in both groups [13]. Study on GLP-1 levels 
during 75 g glucose loading in a Japanese population 
with normal glucose tolerance showed that GLP-1 
levels increased post glucose loading from fasting 
state and the peaked levels was observed at 60 
minutes and declined until the end of observation at 
180 minutes [14]. Another study in Japanese by 
Kozawa et al., on incretin secretion in obese and non-
obese subjects with T2DM and non-diabetic revealed 
that the peaked GLP-1 levels was observed in 30 
minutes and declined until 180 minutes observation. 
Among the 3 groups of subjects, the peak of GLP-1 
levels was tended to be higher in obese diabetic, and 
the lowest in a non-obese diabetic. The two finding 
from Japanese studies is different from our study and 
other studies which the peaked GLP-1 levels were 
found at 15 minutes [15].
 
 
In general it can be concluded that pattern of 
GLP-1 levels is similar in subjects with lean 
normoglycemia, obesity, and glucose intolerance 
which increased post glucose loading and achieving 
the peak levels at around 15-30 minutes and declining 
thereafter until 120-180 minutes of observation; but 
normal or lean subjects have higher GLP-1 levels than 
those with obesity, prediabetes or T2DM. If we 
compare between our study and other studies, 
especially in Caucasians, increasing response of 
GLP-1 at 15 minutes post-glucose loading from the 
fasting state in our study was not as steep as other 
studies have observed. We do not know the certain 
reasons, but we assume that the blunted response of 
GLP-1 may cause T2DM earlier in the Indonesian 
population. We also could not explain the 
phenomenon of increased GLP-1 levels at 120 
minutes in non-obese subjects in this study.  
In conclusion, the patterns of GLP-1 levels 
post glucose loading were similar in obese and non-
obese subjects, which increased from fasting state to 
post glucose loading and reaching the peak levels at 
15 minutes and then declining until the end of 
observation, except in non-obese subjects where 
GLP-1 levels were increased in 120 minutes. There 
was a tendency of lower GLP-1 levels in fasting state 
and post-glucose loading in obese subjects compared 
to non-obese subjects.  
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